SOLICITATION NOTICE
A -- Laboratory Testing
- Notice Date
- 5/6/2010
- Notice Type
- Combined Synopsis/Solicitation
- NAICS
- 541380
— Testing Laboratories
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Heart, Lung and Blood Institute, Rockledge Dr. Bethesda, MD, Office of Acquisitions, 6701 Rockledge Dr RKL2/6100 MSC 7902, Bethesda, Maryland, 20892-7902
- ZIP Code
- 20892-7902
- Solicitation Number
- NHLBI-PB-(HG)-2010-160-RSF
- Archive Date
- 5/30/2010
- Point of Contact
- Rashida S. Ferebee, Phone: 3014352605
- E-Mail Address
-
ferebeers@nhlbi.nih.gov
(ferebeers@nhlbi.nih.gov)
- Small Business Set-Aside
- Total Small Business
- Description
- THIS ANNOUNCEMENT CONSTITUTES THE ONLY SOLICITATION AND A SEPARATE SOLICITATION WILL NOT BE ISSUED. This is a combined synopsis/solicitation for commercial services prepared in accordance with the format in Subpart 12.6 under Simplified Acquisition procedures in Subpart 13.5 as supplemental with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested and a written solicitation will not be issued. The solicitation number for this acquisition is NHLBI-PB-(HG)-2010-160-RSF and is being issued as a Request for Quote. The incorporated provisions and clauses are those in effect through Federal Acquisition Circular 05-40. This acquisition will be processed under Simplified Acquisition Procedures. The associated North American Industry Classification System (NAICS) Code is 541380. The National Institute Human Genome Research Institute (NHGRI), National Institutes of Health (NIH), has a requirement for site directed mutagenesis and assay development of 26 mutations and the transcriptional activation assay of mutants. The period of performance is six months after project initiation. This requirement is set-aside for small business. BACKGROUND: One of the principal goals of the National Human Genome Research Institute (NHGRI) is to provide state of the art genomics analysis to deliver personalized medicine to its research participants and patient families. As technical advances have allowed increased detection of genetic variation among patients the need for an increased understanding of the nature of these sequence variations has increased as well. A functional genomics component to the characterization of detectable sequence variations is essential to inform the clinicians and families of the medical significance of the genetic findings detected in molecular studies. Such information is essential for accurate genetic counseling in specific families as well as to formulate a general understanding of just who is at risk for disease and who is not. The human GLI2 gene is one of the most commonly detected targets of mutation among HPE patients; however, as researchers and clinicians is frequently difficult to distinguish normal genetic variation from medically significant findings. This contract is specifically designed to test the medical relevance of a panel of at least 26 genetic variations in this gene that have been described in patient populations with HPE and related clinical findings. The functional consequences of this extensive panel of changes (the largest compilation in the world) will be compared simultaneously in order to determine relative detrimental effects and serve to provide personalized genetic information. An aggregate statistic will be measured that can guide the interpretation of new variants detected in the future. By such a comparison, NHGRI aims to provide data that will allow clinicians and researchers to better appreciate the role that the human GLI2 gene plays in human disease and allow for the characterization of links between particular genetic alterations and the resulting medical findings (i.e. a genotype-phenotype correlation). Holoprosencephaly (HPE) is the most common developmental defect of the forebrain in humans and occurs in 1 out of 250 pregnancies. The resulting malformation has a tremendous impact on pregnancy viability and early infant mortality. The Muenke lab at NHGRI has been leading the medical community in the identification of genetic risk factors for this severe condition. At least 12 genetic loci have been implicated as potential causes for HPE including the human GLI2 gene that is the subject of this contract. Statement of Work: This requirement has two key components: 1) the generation of all 26 individual genetic alterations in the human GLI2 gene in the form of 26 different plasmid DNAs with sequence verified changes introduced by site-directed mutagenesis of the normal gene supplied to them from the Muenke lab; 2) the establishment of a functional test that compares the activity of these 26 changes to the biological effects of the normal gene. The NIH will provide the contractor with the test cell line to be used in this analysis along with published protocols for setting up the assay. The contractor will have the responsibility to perform the assays and provide publication quality results. The data provided is intended for publication in the medical literature to share with clinicians around the world the types of changes that are associated with disease risk and those that are not. The Offeror must include a completed copy of the following provisions: 1) FAR Clause 52.212-1 Instructions to Offerors Commercial; 2) FAR Clause 52.212-2, Evaluation Commercial Items. As stated in FAR Clause 52.212-2 (a), The Government will award a contract resulting from this solicitation to the responsible offeror whose offer conforming to the solicitation will be most advantageous to the Government, price and other factors considered. 3) FAR Clause 52.212-3, Offeror Representations and Certifications Commercial Items; 4) FAR Clause 52.212-4, Contract Terms and Conditions Required To Implement Statues or Executive Orders Commercial Items, Contract Terms and Conditions Commercial Items; and 5) FAR Clause 52.212-5, Contract Terms and Conditions Required to Implement Statutes or Executive Orders Commercial Items Deviation for Simplified Acquisitions. The offeror must include in their quotation, the unit price, the list price, shipping and handling costs, the delivery period after contract award, the prompt payment discount terms, the F.O.B. Point (Destination or Origin), the Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size. Note: In order to receive an award from the NHLBI contractors must have a valid registration in the Central Contractor Registration (CCR) www.ccr.gov. The clauses are available in full text at http://www.arnet.gov/far. Quotes are due May 15, 2010 by 9:00 am Eastern Standard Time. The award will be made based upon the requirements specified in this combined solicitation/synopsis, and to the offerer providing the best value in meeting the Government's requirements. The offerors must provide documentation in support of the specified requirements. The Government intends to evaluate offerors and may award a contract without discussions with Offerors. Therefore, the initial offer should contain the offerors best terms from a technical and price standpoint. However, the Government reserves the right to conduct discussions if later it is determined by the Contracting Officer to be necessary. The Government may reject any or all offers, waive informalities and minor irregularities in offers received. The quote must reference the Solicitation number NHLBI-PB-(HG)-2010-160-RSF. All responsible sources may submit a proposal which if timely received shall be considered by the agency. Proposals must be submitted in writing to the National, Heart, Lung and Blood Institute, Office of Acquisitions, Procurement Branch, 6701 Rockledge Drive, Suite 6145, Bethesda, MD 20892-7902, Attention: Rashida Ferebee. Response may be submitted electronically to ferebeers@nhlbi.nih.gov. Quotes will be evaluated based on past performance and the requirements specified in this combined solicitation/synopsis equally.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NHLBI/NHLBI-PB-(HG)-2010-160-RSF/listing.html)
- Place of Performance
- Address: National Institutes of Health/NHGRI, Bethesda, Maryland, 20892, United States
- Zip Code: 20892
- Zip Code: 20892
- Record
- SN02142902-W 20100508/100506235515-500b3983e29064cf1f977709903ed9a9 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |